Trial Information
Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension
Inclusion Criteria:
- Patients with pulmonary arterial hypertension with New York Heart Association stage
II - III disease will be eligible for recruitment in the patient portion of the
trial. Interested healthy age matched volunteers will also be recruited.
Exclusion Criteria:
- Patients and volunteers will be excluded if they have significant co-morbidities
including other cardiorespiratory disease, metabolic abnormalities including diabetes
or thyroid disorders. They will be excluded if they cannot safely exercise and
perform a six minute walk test or if they are wheelchair bound.
Type of Study:
Observational
Study Design:
Observational Model: Cohort
Outcome Measure:
Plasma growth and differentiation factor 15 levels in participants with and without muscle wasting
Outcome Description:
Muscle wasting will be defined by quadriceps cross sectional area measured by ultrasound
Outcome Time Frame:
30 months
Safety Issue:
No
Principal Investigator
Stephen J Wort, MBBS
Investigator Role:
Principal Investigator
Investigator Affiliation:
Imperial College / Royal Brompton Hospital
Authority:
United Kingdom: National Institute for Health Research
Study ID:
13IC0457
NCT ID:
NCT01847716
Start Date:
May 2013
Completion Date:
November 2015
Related Keywords:
- Muscle Weakness
- Pulmonary Arterial Hypertension
- Muscle weakness
- Pulmonary arterial hypertension
- Transforming growth factor beta
- Growth and differentiation factor 15
- Asthenia
- Hypertension, Pulmonary
- Hypertension
- Muscle Weakness
- Paresis